Search
Drugs Made In America Acquisition II Ord Shs
DMIIAdd to Watchlist
10.010USD
-0.010-0.10%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
637.64MMarket Cap
31.77P/E TTM
More Details of Drugs Made In America Acquisition II Ord Shs Company
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition II Ord Shs Info
Ticker SymbolDMII
Company nameDrugs Made In America Acquisition II Corp
IPO dateSep 25, 2025
CEOStockwell (Lynn)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address1 East Broward Boulevard
CityFT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone19548703099
Website
Ticker SymbolDMII
IPO dateSep 25, 2025
CEOStockwell (Lynn)
Company Executives of Drugs Made In America Acquisition II Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Drugs Made In America Acquisition II LLC
4.64%
Magnetar Capital Partners LP
4.24%
Glazer Capital, LLC
3.69%
First Trust Capital Management L.P.
3.25%
Conaway (Charles C.)
3.14%
Other
81.04%
Shareholders
Shareholders
Proportion
Drugs Made In America Acquisition II LLC
4.64%
Magnetar Capital Partners LP
4.24%
Glazer Capital, LLC
3.69%
First Trust Capital Management L.P.
3.25%
Conaway (Charles C.)
3.14%
Other
81.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.83%
Investment Advisor/Hedge Fund
16.78%
Investment Advisor
8.57%
Individual Investor
8.48%
Corporation
6.74%
Pension Fund
2.12%
Research Firm
1.24%
Bank and Trust
0.20%
Other
26.04%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
1
666.67K
0.00%
--
2026Q1
58
37.42M
58.75%
+33.66M
2025Q4
7
3.04M
4.64%
+3.04M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Drugs Made In America Acquisition II LLC
4.83M
7.37%
+4.83M
--
Dec 03, 2025
Magnetar Capital Partners LP
2.70M
4.12%
+2.70M
--
Dec 31, 2025
Glazer Capital, LLC
2.35M
3.58%
+2.35M
--
Dec 31, 2025
First Trust Capital Management L.P.
2.07M
3.15%
+2.07M
--
Dec 31, 2025
Conaway (Charles C.)
2.00M
3.05%
+2.00M
--
Dec 03, 2025
Hudson Bay Capital Management LP
1.97M
3%
+1.97M
--
Dec 31, 2025
Wolverine Asset Management, LLC
1.06M
1.62%
+1.06M
--
Dec 31, 2025
Tenor Capital Management Co., L.P.
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Polar Asset Management Partners Inc.
1.50M
2.29%
+1.50M
--
Dec 31, 2025
Millennium Management LLC
1.50M
2.29%
+1.50M
--
Dec 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
